Patients with diabetes and end stage renal disease (ESRD) are at high risk of hypoglycemia. The prevalence and outcomes among hospitalized patients with hypoglycemia and ESRD in the U.S. is not known. Accordingly, we compared the outcomes of patients hospitalized for hypoglycemia with and without ESRD in a U.S. nationwide cohort. We searched the National Inpatient Sample (largest public inpatient database in the U.S.), for adult patients (>18 years) in 2014. We used ICD9 codes to identify admissions for hypoglycemia (primary diagnosis) and ESRD (secondary diagnosis), defined as stage 5 chronic kidney disease, with or without dialysis. Among 97,445 patients admitted for hypoglycemia, 11,285 (11.6%) had ESRD. Patients with ESRD were more likely of African-American and Hispanic race, and had a higher mortality rate, longer length-of-stay (LOS) and higher hospitalization costs compared to those without ESRD (Table). In multivariate analysis, ESRD was significantly associated with an increased odds for mortality (OR 2.92, 95% CI 1.98, 4.29, p<0.01), longer LOS (p<0.001) and higher hospitalization costs (p<0.001). Among patients with hypoglycemia, ESRD is common (11.5%) and is associated with a 3-fold increase in mortality, longer LOS and higher hospitalization costs. Further research on treatment strategies to decrease the burden of hypoglycemia in this population is needed.

Characteristics Hypoglycemia with ESRD n: 11,285 (11.6%) Hypoglycemia without ESRD n: 89,160 (88.4%) p-value 
Age, mean years (±SD) 60.5 (30.8) 63.4 (41.8) <0.001 
Female, n (%) 4,695 (41.6) 35,940 (40.3) 0.9 
Race, Caucasian, n (%) 4,294 (39) 51,000 (57) <0.001 
Race, African-American, n (%) 4,090 (38) 18,000 (20) <0.001 
Ethnicity, Hispanics, n (%) 1,725 (16) 10,000 (11) <0.001 
Hospital Mortality, n (%) 220 (1.95) 590 (0.67) <0.001 
LOS, mean days (±SD) 6.4 (18.5) 5.1 (11.9) <0.001 
Costs, mean US$ (±SD) 13,810 (43,448) 9,859 (34,040) <0.001 
Characteristics Hypoglycemia with ESRD n: 11,285 (11.6%) Hypoglycemia without ESRD n: 89,160 (88.4%) p-value 
Age, mean years (±SD) 60.5 (30.8) 63.4 (41.8) <0.001 
Female, n (%) 4,695 (41.6) 35,940 (40.3) 0.9 
Race, Caucasian, n (%) 4,294 (39) 51,000 (57) <0.001 
Race, African-American, n (%) 4,090 (38) 18,000 (20) <0.001 
Ethnicity, Hispanics, n (%) 1,725 (16) 10,000 (11) <0.001 
Hospital Mortality, n (%) 220 (1.95) 590 (0.67) <0.001 
LOS, mean days (±SD) 6.4 (18.5) 5.1 (11.9) <0.001 
Costs, mean US$ (±SD) 13,810 (43,448) 9,859 (34,040) <0.001 

Disclosure

R.J. Galindo: None. C.R. Hurtado: None. F.J. Pasquel: Consultant; Self; Merck Sharp & Dohme Corp., Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc. P. Vellanki: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. G.E. Umpierrez: Research Support; Self; Sanofi US, Merck & Co., Inc., Novo Nordisk Inc., AstraZeneca. Advisory Panel; Self; Sanofi, Intarcia Therapeutics, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.